Dr Reinhold Kreutz from Charité - Universitätsmedizin Berlin, Germany, presents the 3 most important recent advances in the treatment of arterial hypertension.
What conditions must be met for a screening colonoscopy to be considered reliable? When should a follow-up colonoscopy be performed sooner than indicated by the surveillance schedule and how long after initial examination?
Other than testing for antiphospholipid antibodies, should thrombophilia testing be performed in patients with a history of recurrent miscarriages or stillbirth?
Which diagnostic testing should be performed in a patient after out-of-hospital sudden cardiac arrest (SCA) if the patient’s history is unknown or noncontributory?
Should patients with neutropenia be screened for aspergillosis, eg, with periodic galactomannan testing? Is a positive galactomannan test result without abnormal radiologic findings an indication to initiate treatment in a patient with neutropenia?
What is the current place of cannabidiol and other cannabinoids in the treatment of epilepsy? How often are OTC cannabinoid preparations used by patients with epilepsy in North America? How does it affect the clinical management of epilepsy?
In view of recent clinical trials, which patients with SLE may benefit most from treatment with a type 1 interferon antagonist? Is the safety profile of this therapy acceptable today, in the era of the mutating SARS-CoV-2 pandemic?
You are one of McMaster leaders in educating medical students. Could you comment on the changes that have taken place in this area over the last several years?
If you were to name the 3 most important recent advances in the fields of allergy and immunology that are relevant for everyday practice, what would they be?
English
Polski
Español
українська
